Genentech, a member of the Roche Group (RHHBY.PK), warned that a counterfeit product, labeled as Avastin or bevacizumab, has been distributed in the United States. Genentech said that Chemical analyses of the counterfeit vials tested to date have confirmed the product does not contain the active ingredients for Avastin.
Genentech said that it is working with the U.S. Food and Drug Administration and law enforcement to aid their evaluations, determine the source of the counterfeit drug, and prevent its further distribution.
Genentech also said that the counterfeits may be labeled as Avastin 400 mg/16 mL, with the lot numbers B86017, B6011 or B6010. The counterfeit product does not look similar to authentic Avastin that is FDA-approved for the treatment of certain cancers in the United States.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.